Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

The consensus meeting for the diagnosis, management and treatment for hepatitis C was held in 45th annual meeting for the Japan Society of Hepatology (JSH) in June 2009 where the recommendations and informative statements were discussed including organizers and presenters. The Several important informative statements and recommendations have been shown. This was the fourth JSH consensus meeting of hepatitis C, however, the recommendations have not been published in English previously. Thus, this is the first report of JSH consensus of hepatitis C. The rate of development of hepatocellular carcinoma (HCC) in HCV‐infected patients in Japan is higher than in the USA, because the average age of the HCV‐infected patients is greater and there are more patients with severe fibrosis of the liver than in the USA. In Japan, more than 60% of HCV‐infected patients are genotype 1b infection, and they show lower response to perinterferon and ribavirin combination treatment. To improve the response rate is also an important issue in our country. To establish the original recommendations and informative statements to prevent the development of HCC is a very important issue in Japan.

[1]  S. Takagi,et al.  Natural History , 2019, Nature.

[2]  Y. Imai,et al.  Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha‐2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses , 2010, Journal of viral hepatitis.

[3]  Y. Imai,et al.  Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirin , 2009, Journal of viral hepatitis.

[4]  Y. Imai,et al.  Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin , 2009, Journal of viral hepatitis.

[5]  Yoshiyuki Suzuki,et al.  Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads , 2009, Digestive Diseases and Sciences.

[6]  M. Sata,et al.  A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan , 2009, Hepatology international.

[7]  Yoshiyuki Suzuki,et al.  Necessities of interferon therapy in elderly patients with chronic hepatitis C. , 2009, The American journal of medicine.

[8]  E. Schiff,et al.  Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. , 2009, Gastroenterology.

[9]  A. Branch,et al.  Mutations in the Hepatitis C Virus core Gene Are Associated with Advanced Liver Disease and Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[10]  Yusuke Nakamura,et al.  A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. , 2009, Gastroenterology.

[11]  G. Everson,et al.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.

[12]  P. Marcellin,et al.  Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b , 2009, Annals of Internal Medicine.

[13]  M. Buti,et al.  141 EXTENDED TREATMENT DURATION IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY , 2009 .

[14]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[15]  B. Bacon,et al.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5‐year follow‐up of 150 patients , 2009, Hepatology.

[16]  T. Arakawa,et al.  Long‐term follow‐up of patients with hepatitis C with a normal alanine aminotransferase , 2009, Journal of medical virology.

[17]  Yoshiyuki Suzuki,et al.  A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response , 2009, Journal of medical virology.

[18]  A. Andriulli,et al.  Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection , 2009, Hepatology.

[19]  Charles M. Rice,et al.  Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.

[20]  T. Ide,et al.  A Randomized Study of Extended Treatment With Peginterferon α-2b Plus Ribavirin Based on Time to HCV RNA Negative–Status in Patients With Genotype 1b Chronic Hepatitis C , 2009, The American Journal of Gastroenterology.

[21]  Y. Kondo,et al.  Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. , 2008, World journal of gastroenterology.

[22]  S. Fargion,et al.  Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. , 2008, Liver.

[23]  O. Weiland,et al.  Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. , 2008, Liver.

[24]  William M. Lee,et al.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. , 2008, The New England journal of medicine.

[25]  N. Tanaka,et al.  Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors , 2008, Hepatology.

[26]  D. Brenner,et al.  Hepatitis C virus–induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity , 2008, Hepatology.

[27]  O. Weiland,et al.  Lower‐than‐standard dose peg‐IFN alfa‐2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight‐based ribavirin , 2008, Journal of viral hepatitis.

[28]  Yoshiyuki Suzuki,et al.  Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. , 2008, Journal of medical virology.

[29]  P. Messa,et al.  Antiviral therapy of hepatitis C in chronic kidney diseases: meta‐analysis of controlled clinical trials , 2008, Journal of viral hepatitis.

[30]  H. Hotta,et al.  Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy , 2008, Hepatology.

[31]  G. Norkrans,et al.  Randomized comparison of 12 or 24 weeks of peginterferon α‐2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection , 2008, Hepatology.

[32]  M. Manns,et al.  Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus , 2008, Hepatology.

[33]  N. Enomoto,et al.  Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. , 2008, Gastroenterology.

[34]  J. Dubuisson,et al.  Early steps of the hepatitis C virus life cycle , 2008, Cellular microbiology.

[35]  A. Macleod KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. , 2008, Kidney international. Supplement.

[36]  Brian L. Pearlman,et al.  Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders , 2007, Hepatology.

[37]  E. Bjornsson,et al.  Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response , 2007, Hepatology.

[38]  Yoshiyuki Suzuki,et al.  Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis , 2007, Hepatology.

[39]  Yoshiyuki Suzuki,et al.  Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b , 2007, Journal of medical virology.

[40]  R. D. de Knegt,et al.  γ‐Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon‐α‐2b in chronic hepatitis C non‐responders , 2007 .

[41]  R. Gish,et al.  Efficacy of interferon alpha‐2b induction therapy before retreatment for chronic hepatitis C , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[42]  Yoshiyuki Suzuki,et al.  Evaluation of long‐term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[43]  M. Diago,et al.  Clinical trial: pharmacodynamics and pharmacokinetics of re‐treatment with fixed‐dose induction of peginterferon α‐2a in hepatitis C virus genotype 1 true non‐responder patients , 2007, Alimentary pharmacology & therapeutics.

[44]  Yoshiyuki Suzuki,et al.  Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. , 2007, Journal of medical virology.

[45]  H. Hotta,et al.  Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b. , 2007, The Journal of infectious diseases.

[46]  P. Messa,et al.  Interferon monotherapy of chronic hepatitis C in dialysis patients: meta‐analysis of clinical trials , 2007, Journal of viral hepatitis.

[47]  R. Stravitz,et al.  Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha , 2007, Hepatology.

[48]  Yoshiyuki Suzuki,et al.  Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C , 2007, Journal of medical virology.

[49]  B. Bacon,et al.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.

[50]  H. Nomura,et al.  Efficacy of low dose long‐term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha‐fetoprotein: A pilot study , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[51]  K. Tanikawa,et al.  A Large-scale, Multicentre, Double-blind Trial of Ursodeoxycholic Acid in Patients with Chronic Hepatitis C , 2022 .

[52]  M. Kurosaki,et al.  Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha‐2b and ribavirin , 2007, Journal of viral hepatitis.

[53]  Milton W. Taylor,et al.  Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy , 2007, Journal of Virology.

[54]  H. Toyoda,et al.  Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection , 2007, Gut.

[55]  Charles M. Rice,et al.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.

[56]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[57]  Yoshiyuki Suzuki,et al.  Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. , 2007, Journal of hepatology.

[58]  Keiji Tanaka,et al.  Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis , 2007, Proceedings of the National Academy of Sciences.

[59]  L. Mariani,et al.  Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis , 2006, Hepatology.

[60]  J. Borovička,et al.  HCV‐related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon α‐2a and ribavirin , 2006, Journal of viral hepatitis.

[61]  L. Rostaing,et al.  Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. , 2006, Transplantation.

[62]  T. Mcgarrity,et al.  Sustained Viral Response to Pegylated Interferon α-2b and Ribavirin in Chronic Hepatitis C Refractory to Prior Treatment , 2006, Digestive Diseases and Sciences.

[63]  Ming‐Lung Yu,et al.  A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C , 2006, Gut.

[64]  Christopher T. Jones,et al.  Diverse CD81 Proteins Support Hepatitis C Virus Infection , 2006, Journal of Virology.

[65]  R. Andrade,et al.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.

[66]  N. Hayashi,et al.  Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[67]  R. Suruki,et al.  Alanine aminotransferase level as a predictor of hepatitis C virus‐associated hepatocellular carcinoma incidence in a community‐based population in Japan , 2006, International Journal of Cancer.

[68]  S. Lemon,et al.  Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. , 2006, Gastroenterology.

[69]  William M. Lee,et al.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[70]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[71]  Yoshiyuki Suzuki,et al.  A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients , 2006, Digestive Diseases and Sciences.

[72]  Y. Shiratori,et al.  Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C , 2006, Hepatology.

[73]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[74]  S. Weinman,et al.  Hepatitis C Virus Core Protein Inhibits Mitochondrial Electron Transport and Increases Reactive Oxygen Species (ROS) Production* , 2005, Journal of Biological Chemistry.

[75]  E. Bini,et al.  A Randomized Trial of Pegylated Interferon α-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.

[76]  Osamu Takeuchi,et al.  IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction , 2005, Nature Immunology.

[77]  T. Nakajima,et al.  A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. , 2005, Journal of hepatology.

[78]  T. Hibi,et al.  Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. , 2005, Hepato-gastroenterology.

[79]  M. Gale,et al.  Evasion of intracellular host defence by hepatitis C virus , 2005, Nature.

[80]  T. Berg,et al.  Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C , 2005 .

[81]  Yoshiyuki Suzuki,et al.  Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.

[82]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[83]  B. Neuschwander‐Tetri,et al.  Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[84]  S. Lemon,et al.  Distinct Poly(I-C) and Virus-activated Signaling Pathways Leading to Interferon-β Production in Hepatocytes* , 2005, Journal of Biological Chemistry.

[85]  H. Te,et al.  Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety , 2005, Digestive Diseases and Sciences.

[86]  S. Lemon,et al.  Regulating Intracellular Antiviral Defense and Permissiveness to Hepatitis C Virus RNA Replication through a Cellular RNA Helicase, RIG-I , 2005, Journal of Virology.

[87]  R. Andrade,et al.  Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.

[88]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[89]  Y. Ohashi,et al.  Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival , 2005, Annals of Internal Medicine.

[90]  F. Fabrizi,et al.  Meta‐analysis: effect of hepatitis C virus infection on mortality in dialysis , 2004, Alimentary pharmacology & therapeutics.

[91]  Y. Imai,et al.  Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response , 2004, Journal of Gastroenterology.

[92]  T. Kawaguchi,et al.  Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. , 2004, The American journal of pathology.

[93]  Y. Imai,et al.  Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy , 2004, Cancer.

[94]  P Martus,et al.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences , 2004, Gut.

[95]  Shizuo Akira,et al.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.

[96]  P. Marcellin,et al.  Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial , 2004, American Journal of Gastroenterology.

[97]  M. Sata,et al.  A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan , 2004, Journal of Gastroenterology.

[98]  William M. Lee,et al.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.

[99]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[100]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[101]  K. Koike,et al.  Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. , 2004, Gastroenterology.

[102]  Aniruddha M. Deshpande,et al.  Standardized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guideline Standardization , 2003, Annals of Internal Medicine.

[103]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[104]  M. Russo,et al.  Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety , 2003, American Journal of Gastroenterology.

[105]  Lin Deng,et al.  Identification of Hepatitis C Virus (HCV) Subtype 1b Strains That Are Highly, or Only Weakly, Associated with Hepatocellular Carcinoma on the Basis of the Secondary Structure of an Amino-Terminal Portion of the HCV NS3 Protein , 2003, Journal of Clinical Microbiology.

[106]  K. Eguchi,et al.  Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection , 2003, Cancer.

[107]  G. Marchesini,et al.  Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. , 2003, Gastroenterology.

[108]  P. Heinrich,et al.  IFN‐α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling‐3 , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  Y. Shiratori,et al.  Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus , 2003, Annals of Internal Medicine.

[110]  Yoshiyuki Suzuki,et al.  Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. , 2002, Journal of hepatology.

[111]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[112]  R. Cortese,et al.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.

[113]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[114]  Warren S. Alexander,et al.  Suppressors of cytokine signalling (SOCS) in the immune system , 2002, Nature Reviews Immunology.

[115]  S. Kubo,et al.  Randomized clinical trial of long‐term outcome after resection of hepatitis C virus‐related hepatocellular carcinoma by postoperative interferon therapy , 2002, The British journal of surgery.

[116]  D. Pessayre,et al.  Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral‐related steatosis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[117]  Frank Scholle,et al.  Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. , 2002, Gastroenterology.

[118]  T. Takayama,et al.  Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. , 2001, Cancer research.

[119]  K. Shimotohno,et al.  Effects of Mutation in Hepatitis C Virus Nonstructural Protein 5A on Interferon Resistance Mediated by Inhibition of PKR Kinase Activity in Mammalian Cells , 2001, Microbiology and immunology.

[120]  P. Marcellin,et al.  Prospective study on anti‐hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA , 2001, Hepatology.

[121]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[122]  E. Schiff,et al.  A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C , 2001, Hepatology.

[123]  G. Barber,et al.  Hepatitis C Virus Nonstructural 5A Protein Induces Interleukin-8, Leading to Partial Inhibition of the Interferon-Induced Antiviral Response , 2001, Journal of Virology.

[124]  K. Koike,et al.  Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. , 2001, Cancer research.

[125]  A. Tamori,et al.  Effects of Long-Term Postoperative Interferon- Therapy on Intrahepatic Recurrence after Resection of Hepatitis C VirusRelated Hepatocellular Carcinoma , 2001, Annals of Internal Medicine.

[126]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[127]  K. Chayama,et al.  Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer , 2000, Hepatology.

[128]  H. Bonkovsky,et al.  Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial , 2000, Hepatology.

[129]  E. Tanaka,et al.  Natural history of acute hepatitis C , 2000, Journal of gastroenterology and hepatology.

[130]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[131]  R. Torella,et al.  Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. , 2000, Gastroenterology.

[132]  R. Levine,et al.  Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial , 2000, Hepatology.

[133]  L. Seeff,et al.  45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults , 2000, Annals of Internal Medicine.

[134]  J. Herrera Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy , 1999, American Journal of Gastroenterology.

[135]  C. Garret,et al.  A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. , 1999, Gastroenterology.

[136]  Y. Rino,et al.  Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus‐associated cirrhosis , 1999, Cancer.

[137]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[138]  D. R. Taylor,et al.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.

[139]  E. Kenny‐Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. , 1999, The New England journal of medicine.

[140]  K. Chayama,et al.  Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis , 1999, Hepatology.

[141]  T. Okanoue,et al.  Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. , 1999, Journal of hepatology.

[142]  L. Rostaing,et al.  Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. , 1998, Journal of the American Society of Nephrology : JASN.

[143]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[144]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[145]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[146]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[147]  Y. Imai,et al.  Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 1998, Annals of Internal Medicine.

[148]  M. Rapicetta,et al.  Correlation between virus genotype and chronicity rate in acute hepatitis C. , 1998, Journal of hepatology.

[149]  M. Mizokami,et al.  A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C , 1998 .

[150]  Aril Frydén,et al.  Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C , 1998, The Lancet.

[151]  H. Scholte,et al.  Mitochondrial Injury , 1997, Drug safety.

[152]  K. Chayama,et al.  The long term efficacy of glycyrrhizin in chronic hepatitis C patients , 1997, Cancer.

[153]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[154]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[155]  M. Urdea,et al.  Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level , 1995, Hepatology.

[156]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[157]  N. Enomoto,et al.  Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. , 1995, The Journal of clinical investigation.

[158]  M. Tong,et al.  Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.

[159]  C. Gil,et al.  Persistent hepatitis C viremia after acute self‐limiting posttransfusion hepatitis C , 1995, Hepatology.

[160]  K. Masuko,et al.  Hepatitis C virus antibodies, viral RNA and genotypes in sera from patients on maintenance haemodialysis , 1994, Journal of viral hepatitis.

[161]  K. Chayama,et al.  Factors predictive of response to interferon‐α therapy in hepatitis C virus infection , 1994, Hepatology.

[162]  K. Chayama,et al.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.

[163]  G. Davis,et al.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C , 1993, The Lancet.

[164]  F. Iber,et al.  Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .

[165]  R. Goldwyn FOLLOW-UP , 1992, Science.

[166]  R. Purcell,et al.  Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.

[167]  D. Laurent,et al.  A randomized study , 2010 .

[168]  Y. Shaobin,et al.  AASLD PRACTICE GUIDELINES:diagnosis,management,and treatment of hepatitis C:an update , 2009 .

[169]  Hirokazu Takahashi,et al.  Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load , 2008, Digestive Diseases and Sciences.

[170]  N. Hayashi,et al.  Virological Response in Patients with Hepatitis C Virus Genotype 1b and a High Viral Load , 2008, Clinical drug investigation.

[171]  K. Okita,et al.  Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. , 2008, Gastroenterology.

[172]  仁科 惣治 Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription , 2008 .

[173]  M. Jadoul,et al.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease , 2008 .

[174]  R. D. de Knegt,et al.  Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[175]  K. Reddy,et al.  Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[176]  William M. Lee,et al.  Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. , 2007, Gastroenterology.

[177]  A. Jaffe,et al.  Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. , 1983, British heart journal.

[178]  G. Sen,et al.  Viruses and interferons. , 2001, Annual review of microbiology.

[179]  P. Bonis Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. , 1999, The New England journal of medicine.

[180]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[181]  O. Weiland,et al.  Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. , 1998, Lancet.

[182]  E. Wildhirt Experience in Germany with Glycyrrhizinic Acid for the Treatment of Chronic Viral Hepatitis , 1994 .

[183]  J. Kirkwood,et al.  Interferon therapy. , 1982, World Health Organization technical report series.

[184]  N. Grace Hepatic iron overload. , 1973, Postgraduate medicine.